| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EN2 |
| Uniprot No | P19622 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 86-210aa |
| 氨基酸序列 | GTCCAGAGGGRGGGAGGEGGASGAEGGGGAGGSEQLLGSGSREPRQNPPC APGAGGPLPAAGSDSPGDGEGGSKTLSLHGGAKKGGDPGGPLDGSLKARG LGGGDLSVSSDSDSSQAGANLGAQP |
| 预测分子量 | 34,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EN2(Engrailed-2)重组蛋白的假设性参考文献示例(仅供格式参考，实际文献需通过学术数据库查询)：
---
1. **文献名称**: *EN2 recombinant protein promotes neuronal differentiation in vitro*
**作者**: Smith A, et al.
**摘要**: 研究报道了重组EN2蛋白通过激活Wnt/β-catenin信号通路，促进小鼠胚胎干细胞向神经元分化的作用机制，为神经再生治疗提供潜在策略。
2. **文献名称**: *Recombinant EN2 as a novel biomarker in prostate cancer diagnosis*
**作者**: Lee JH, et al.
**摘要**: 通过ELISA检测发现，重组EN2蛋白在前列腺癌患者尿液中显著高表达，提示其作为非侵入性诊断标志物的临床价值。
3. **文献名称**: *Crystal structure and functional analysis of EN2 recombinant protein*
**作者**: Garcia R, et al.
**摘要**: 解析了重组EN2蛋白的晶体结构，揭示其DNA结合域的关键氨基酸残基，为靶向EN2的分子设计提供结构基础。
4. **文献名称**: *EN2 recombinant protein enhances drug resistance in breast cancer cells*
**作者**: Wang X, et al.
**摘要**: 实验表明，重组EN2蛋白通过上调ABC转运蛋白表达，增强乳腺癌细胞对化疗药物的耐药性，提示靶向EN2可能改善治疗效果。
---
**注意**：以上内容为模拟示例，实际文献需查阅PubMed、Web of Science等平台(关键词：EN2 recombinant protein/Engrailed-2 recombinant)。真实研究可重点关注EN2在癌症、神经发育或表观遗传调控中的功能。
EN2 (Engrailed-2) is a homeodomain-containing transcription factor encoded by the *EN2* gene, part of the evolutionarily conserved Engrailed family. Initially identified for its role in embryonic development, EN2 regulates patterning of the midbrain-hindbrain boundary and limb morphogenesis in vertebrates. Beyond embryogenesis, EN2 has gained attention for its ectopic expression in cancers, particularly prostate, breast, and glioblastoma, where it promotes tumor progression by modulating cell proliferation, invasion, and angiogenesis.
Recombinant EN2 protein is produced using genetic engineering techniques, typically expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian cells) to ensure proper folding and post-translational modifications. The protein is purified via affinity tags (e.g., His-tag) and chromatography, retaining functional domains critical for DNA binding and transcriptional regulation. Its molecular weight ranges between 40-45 kDa, depending on expression systems and modifications.
In research, recombinant EN2 serves as a tool to study developmental pathways (e.g., Wnt, SHH) and cancer mechanisms. It aids in identifying EN2-interacting proteins, mapping DNA-binding sites, and screening inhibitors. Clinically, EN2 is explored as a diagnostic biomarker (e.g., urinary EN2 in prostate cancer) and a therapeutic target. Recent studies also investigate its role in neurological disorders, including autism spectrum disorders, linking its dysregulation to synaptic dysfunction.
Despite progress, challenges remain in understanding EN2's context-dependent roles and optimizing recombinant forms for therapeutic applications. Ongoing research focuses on its dual functions in development and disease, bridging molecular insights to translational potential.
×
